Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Disposition of l-738,167, A Potent and Long-Acting Fibrinogen Receptor Antagonist, in Dogs

Dose-Dependent Pharmacokinetics

Thomayant Prueksaritanont, Lynn M. Gorham, Jeanne A. Naue, Terrence G. Hamill, Ben C. Askew and Kamlesh P. Vyas
Drug Metabolism and Disposition March 1997, 25 (3) 355-361;
Thomayant Prueksaritanont
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lynn M. Gorham
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeanne A. Naue
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Terrence G. Hamill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ben C. Askew
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kamlesh P. Vyas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Dose-Dependent Pharmacokinetics

Abstract

l-738,167 is a potent and long-acting fibrinogen receptor antagonist and may be useful for treatment of chronic thrombotic occlusive disorders. The purposes of this study were to characterize the metabolism and disposition of l-738,167, and to investigate factors affecting its pharmacokinetic behaviors in dogs, one of the animal models used in pharmacological and toxicological studies. In vitro and in vivoexperiments indicated that l-738,167 was not metabolized to any appreciable extent in dogs. Biliary excretion was found to be the major route (∼75%) of drug elimination. Following 1 and 3 μg/kg iv doses, blood pharmacokinetics of l-738,167 were linear. Total blood clearance (CLB ) was much lower than hepatic blood flow, and the apparent volume of distribution at steady-state (Vdss,B ) was comparable with blood volume. Blood pharmacokinetics in the dose range of 3–250 μg/kg were dose-dependent; both CLB andVdss,B for l-738,167 increased markedly with increasing doses. However, the terminal half-life (t½) was dose-independent, with a mean value of ∼4 days. l-738,167 was found to bind negligibly to dog plasma proteins. Determinations of whole blood (WB), platelet-rich plasma, and platelet-poor plasma concentrations after several intravenous doses of [3H]l-738,167 revealed significant concentration-dependent binding of the compound to platelets. Kinetic analysis of the platelet binding indicated thatl-738,167 was bound to dog platelets with high affinity (apparent Kd ∼ 1 nM platelet-poor plasma concentration) and relatively low capacity (∼70 nM WB concentration). Findings are consistent with the binding kinetics ofl-738,167 to glycoprotein IIb/IIIa (GP IIb/IIIa) receptor, supporting that GP IIb/IIIa was the primary binding component on the platelets. It was concluded that the dose-dependent pharmacokinetics ofl-738,167 were the consequence of the concentration-dependent drug-platelet binding. Due to this extensive platelet binding, l-738,167, when given in therapeutic doses or lower, resided primarily in the vascular compartment—the site of pharmacological action. At doses exceeding the receptor binding capacity, the excess amount or the unbound drug was eliminated rapidly. In all cases, the equally long t½ ofl-738,167 was also a consequence of the high-affinity binding to platelets, in good agreement with its prolonged pharmacodynamic profile.

Footnotes

  • Send reprint requests to: Dr. Thomayant Prueksaritanont, Department of Drug Metabolism, WP 26A-2044, Merck Research Laboratories, West Point, PA 19486.

  • ↵2 T. G. Hamill, B. C. Askew, G. D. Hartman, D. A. Claremon, C. J. McIntyre, and D. Burns, manuscript in preparation.

  • ↵3 J. J. Cook, G. R. Sitko, M. A. Holahan, M. T. Stranieri, B. C. Askew, D. A. Claremon, J. J. Baldwin, G. D. Hartman, R. J. Gould, and J. J. Lynch, manuscript in preparation.

  • Abbreviations used are::
    GP IIb/IIIa
    glycoprotein IIb/IIIa
    RGD
    tripeptide sequence arginine-glycine-aspartic acid
    UDPGA
    UDP-glucuronic acid
    WB
    whole blood
    PRP
    platelet-rich plasma
    PPP
    platelet-poor plasma
    CLB
    total blood clearance
    AUC
    area under the blood concentration-time curve
    Vdss,B
    apparent volume of distribution at steady state
    t½
    terminal half-life
    • Received September 6, 1996.
    • Accepted November 25, 1996.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition
Vol. 25, Issue 3
1 Mar 1997
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Disposition of l-738,167, A Potent and Long-Acting Fibrinogen Receptor Antagonist, in Dogs
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Disposition of l-738,167, A Potent and Long-Acting Fibrinogen Receptor Antagonist, in Dogs

Thomayant Prueksaritanont, Lynn M. Gorham, Jeanne A. Naue, Terrence G. Hamill, Ben C. Askew and Kamlesh P. Vyas
Drug Metabolism and Disposition March 1, 1997, 25 (3) 355-361;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Disposition of l-738,167, A Potent and Long-Acting Fibrinogen Receptor Antagonist, in Dogs

Thomayant Prueksaritanont, Lynn M. Gorham, Jeanne A. Naue, Terrence G. Hamill, Ben C. Askew and Kamlesh P. Vyas
Drug Metabolism and Disposition March 1, 1997, 25 (3) 355-361;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • P450 cell lines for xenobiotic metabolite generation
  • Human ADME properties of abrocitinib
  • Impact of physiological microenvironments on HepaRG cells
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics